These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28444254)

  • 21. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
    Fiorino G; Manetti N; Armuzzi A; Orlando A; Variola A; Bonovas S; Bossa F; Maconi G; DʼIncà R; Lionetti P; Cantoro L; Fries W; Annunziata ML; Costa F; Terpin MM; Biancone L; Cortelezzi CC; Amato A; Ardizzone S; Danese S; Guidi L; Rizzuto G; Massella A; Andriulli A; Massari A; Lorenzon G; Ghione S; Kohn A; Ventra A; Annese V;
    Inflamm Bowel Dis; 2017 Feb; 23(2):233-243. PubMed ID: 28092307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study.
    Schmitz EMH; Benoy-De Keuster S; Meier AJL; Scharnhorst V; Traksel RAM; Broeren MAC; Derijks LJJ
    Clin Rheumatol; 2017 Sep; 36(9):2129-2134. PubMed ID: 28593609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
    Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
    J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S; Gabbani T; Annese V
    World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
    Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
    Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis.
    Holroyd CR; Parker L; Bennett S; Zarroug J; Underhill C; Davidson B; Armstrong R; Harvey NC; Dennison E; Cooper C; Edwards CJ
    Clin Exp Rheumatol; 2018; 36(1):171-172. PubMed ID: 29352847
    [No Abstract]   [Full Text] [Related]  

  • 28. Infliximab Biosimilars in the Age of Personalized Medicine.
    Kang J; Pisupati K; Benet A; Ruotolo BT; Schwendeman SP; Schwendeman A
    Trends Biotechnol; 2018 Oct; 36(10):987-992. PubMed ID: 29861288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum sickness-like disease after switching to biosimilar infliximab.
    Scherlinger M; Schaeverbeke T; Truchetet ME;
    Rheumatology (Oxford); 2017 Nov; 56(11):2032-2034. PubMed ID: 28977481
    [No Abstract]   [Full Text] [Related]  

  • 30. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
    Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro Benallal D; Benítez Roldán A; Merino V; Ramirez G; Calleja-Hernández MA; Caunedo Álvarez A; Romero Gómez M
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1290-1295. PubMed ID: 28902041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.
    Farkas K; Molnár T; Szepes Z
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):695-702. PubMed ID: 24738535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
    Dumitrescu G; Dahan K; Treton X; Corcos O; Bouhnik Y; Stefanescu C
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):249-51. PubMed ID: 26114187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective Evaluation of Cytomegalovirus Time-course Kinetics in Colonic Biopsies from Patients with Moderate-to-severe Ulcerative Colitis Following Infliximab Treatment: A Prospective Study.
    Boivineau L; Le Méhauté A; Roblin X
    J Crohns Colitis; 2020 Nov; 14(11):1644-1645. PubMed ID: 32343774
    [No Abstract]   [Full Text] [Related]  

  • 37. Biosimilar medicines for psoriasis. Positioning of the Mexican Academy of Dermatology.
    García-Hidalgo L; Méndez-Flores S; Carrillo-Vázquez S; Estrada-Aguilar L; García-Salazar MDR; Gómez-Flores M; López-Tello A; Charli-Joseph Y; Maldonado-García C; Serrano-Jaén L
    Gac Med Mex; 2020; 156(Supl):1-14. PubMed ID: 32484168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positioning Infliximab and Vedolizumab in the Treatment of Moderate-to-Severe Ulcerative Colitis.
    Sheehan JL; Cohen-Mekelburg S
    Gastroenterology; 2022 May; 162(6):1764-1765. PubMed ID: 34864070
    [No Abstract]   [Full Text] [Related]  

  • 39. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
    Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.